Steven Cohen Moon Lake Immunotherapeutics Transaction History
Point72 Asset Management, L.P.
- $51 Billion
- Q3 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 9,800 shares of MLTX stock, worth $125,146. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,800
Previous 186,568
94.75%
Holding current value
$125,146
Previous $8.81 Million
99.21%
% of portfolio
0.0%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding MLTX
# of Institutions
181Shares Held
38.5MCall Options Held
4.13MPut Options Held
1.51M-
Bvf Inc San Francisco, CA19.8MShares$252 Million7.66% of portfolio
-
Avoro Capital Advisors LLC New York, NY2MShares$25.5 Million0.2% of portfolio
-
Cormorant Asset Management, LP Boston, MA1.99MShares$25.5 Million2.28% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.7MShares$21.7 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.5MShares$19.2 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $472M
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...